Takeda’s oveporexton shows broader benefits in Phase III narcolepsy studies
Japanese pharma Takeda (TSYO 4502) has reported further Phase III data showing that oveporexton improved daily function, cognition and nighttime sleep in people with narcolepsy type 1 (NT1), adding to the case for a drug that could become the first approved orexin agonist for the disorder.
The findings, presented at SLEEP 2026 in Baltimore, build on earlier results from the global, placebo-controlled FirstLight and RadiantLight studies. Oveporexton, also known as TAK-861, is an investigational oral orexin receptor 2-selective agonist designed to address the orexin deficiency that causes NT1.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze